0001193125-13-172578.txt : 20130425 0001193125-13-172578.hdr.sgml : 20130425 20130425104426 ACCESSION NUMBER: 0001193125-13-172578 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20130425 DATE AS OF CHANGE: 20130425 GROUP MEMBERS: ODYSSEUS ACQUISITION CORP. GROUP MEMBERS: VALEANT PHARMACEUTICALS INTERNATIONAL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Obagi Medical Products, Inc. CENTRAL INDEX KEY: 0001375247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954658730 STATE OF INCORPORATION: DE FISCAL YEAR END: 0710 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-82589 FILM NUMBER: 13781441 BUSINESS ADDRESS: STREET 1: 3760 KILROY AIRPORT WAY STREET 2: #500 CITY: LONG BEACH STATE: CA ZIP: 90806 BUSINESS PHONE: 562-628-1007 MAIL ADDRESS: STREET 1: 3760 KILROY AIRPORT WAY STREET 2: #500 CITY: LONG BEACH STATE: CA ZIP: 90806 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 SC TO-T/A 1 d528280dsctota.htm SC TO-T/A SC TO-T/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 7)

OBAGI MEDICAL PRODUCTS, INC.

(Name of Subject Company (Issuer))

Odysseus Acquisition Corp.

a wholly owned subsidiary of

Valeant Pharmaceuticals International

a wholly owned subsidiary of

Valeant Pharmaceuticals International, Inc.

(Names of Filing Persons (Offerors))

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class Of Securities)

67423R108

(CUSIP Number of Class of Securities)

Robert Chai-Onn

Executive Vice President, General Counsel and Corporate Secretary

Valeant Pharmaceuticals International, Inc.

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada, H7L 4A8

(949) 461-6000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

With copies to:

Stephen F. Arcano

Marie L. Gibson

Skadden, Arps, Slate, Meagher & Flom LLP

4 Times Square

New York, NY 10036

(212) 735-3000

CALCULATION OF FILING FEE


Transaction Valuation(1)		Amount Of Filing Fee(2)
$418,419,312		$57,072.39

(1)

Estimated solely for purposes of calculating the filing fee. The transaction value was determined by multiplying (x) $24.00 (i.e., the tender offer price) by 17,434,138, the estimated maximum number of shares of common stock of Obagi Medical Products, Inc. to be acquired in the tender offer.

(2)

The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for Fiscal Year 2013, issued August 31, 2012, revised October 2012, by multiplying the transaction value by 0.00013640.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


Amount Previously Paid: $57,072.39		Filing Party: Odysseus Acquisition Corp., Valeant Pharmaceuticals International and Valeant Pharmaceuticals International, Inc.

Form or Registration No.: Schedule TO-T, Schedule TO-T/A Date Filed: March 26, 2013, April 4, 2013

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

third-party tender offer subject to Rule 14d-1.

issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 7 (“Amendment No. 7”) amends and supplements the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 26, 2013 and amended on April 4, 2013 and April 5, 2013, April 12, 2013, April 22, 2013, April 23, 2013 and April 24, 2013 (as amended, the “Schedule TO”) and relates to the offer of Odysseus Acquisition Corp., a Delaware corporation (the “Purchaser”), to purchase all outstanding shares of common stock, par value $0.001 (the “Shares”), of Obagi Medical Products, Inc., a Delaware corporation (“Obagi”), at a price of $24.00 per Share, net to the seller in cash, without interest (less any required withholding taxes) (the “Offer Price”), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated March 26, 2013 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the related Letter of Transmittal (together with any amendments or supplements thereto, the “Letter of Transmittal” and, together with the Offer to Purchase, the “Offer”), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. The Purchaser is a wholly owned subsidiary of Valeant Pharmaceuticals International, a Delaware corporation (“VPI”), which is a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., a Canadian corporation (“Valeant”). This Amendment No. 7 is being filed on behalf of VPI, Valeant and the Purchaser.

All the information set forth in the Offer to Purchase, to the extent incorporated by reference therein, is hereby amended and supplemented as set forth below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Offer to Purchase.

ITEM 11.

ADDITIONAL INFORMATION

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following text thereto:

“The Offer expired at 12:00 midnight, New York City time, on April 25, 2013. The Depositary for the Offer has advised VPI and the Purchaser that, as of the expiration of the Offer, a total of 14,708,133 Shares had been validly tendered into and not withdrawn from the Offer, representing approximately 84.12% of the 17,484,138 outstanding Shares as of 12:00 midnight, New York City time, on April 25, 2013. Additionally, the Depositary has advised VPI and the Purchaser that an additional 938,189 Shares had been tendered by notice of guaranteed delivery. The Purchaser has accepted for payment all Shares validly tendered into the Offer and not properly withdrawn.

Pursuant to the terms of the Merger Agreement, the Purchaser intends to exercise its option to purchase at a purchase price of $24.00 per Share directly from Obagi an additional number of Shares sufficient to give the Purchaser ownership of at least 90% of Obagi’s then outstanding Shares (on a fully diluted basis), when combined with the Shares purchased by the Purchaser in the Offer.

Following the purchase of Shares in the Offer and the issuance of Shares pursuant to the Top-Up Option, the Purchaser will have sufficient voting power to approve the Merger without the affirmative vote of any other stockholder of Obagi. Accordingly, the Purchaser and VPI intend to consummate a short-form merger in which the Purchaser will merge with and into Obagi, with Obagi surviving the Merger and continuing as a wholly-owned subsidiary of VPI. As a result of the Merger, each Share issued and outstanding immediately prior to the Effective Time, other than (i) Shares owned, directly or indirectly, by VPI or the Purchaser immediately prior to the Effective Time or held by Obagi immediately prior to the Effective Time, all of which will be cancelled and cease to exist, and (ii) Shares held by stockholders of Obagi who properly exercised their appraisal rights under Section 262 of the DGCL, will be converted into the right to receive an amount of cash equal to the Offer Price, without interest (less any applicable withholding taxes). All Shares that are converted into the right to receive the Offer Price will be canceled and cease to exist. Promptly following consummation of the Merger, VPI intends to cause all Shares to be delisted from the Nasdaq and deregistered under the Exchange Act.

On April 25, 2013, Valeant issued a press release announcing the expiration and results of the Offer. The full text of the press release is attached as Exhibit (a)(5)(H) to the Schedule TO and is incorporated herein by reference.”

ITEM 12.

EXHIBITS

Item 12 of the Schedule TO is hereby amended and supplemented to add the following exhibit:

(a)(5)(H) Press Release issued by Valeant Pharmaceuticals International, Inc. on April 25, 2013.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 25, 2013


ODYSSEUS ACQUISITION CORP.

By:		/s/ Robert Chai-Onn
Name:		Robert Chai-Onn
Title:		Secretary

VALEANT PHARMACEUTICALS INTERNATIONAL

By:		/s/ Robert Chai-Onn
Name:		Robert Chai-Onn
Title:		Executive Vice President, General Counsel and Corporate Secretary

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

By:		/s/ Robert Chai-Onn
Name:		Robert Chai-Onn
Title:		Executive Vice President, General Counsel and Corporate Secretary

EXHIBIT INDEX


(a)(1)(A)		Offer to Purchase, dated March 26, 2013. *

(a)(1)(B)		Form of Letter of Transmittal. *

(a)(1)(C)		Form of Notice of Guaranteed Delivery. *

(a)(1)(D)		Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. *

(a)(1)(E)		Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. *

(a)(1)(F)		Form of Internal Revenue Service Form W-9 (Request for Taxpayer Identification Number and Certification), including instructions for completing the form. *

(a)(2)		Not applicable.

(a)(3)		Not applicable.

(a)(4)		Not applicable.

(a)(5)(A)		Press Release issued by Valeant Pharmaceuticals International, Inc. on March 20, 2013 (incorporated by reference to Exhibit (a)(5)(A) to the Tender Offer Statement on Schedule TO-C filed by Odysseus Acquisition Corp., Valeant Pharmaceuticals International and Valeant Pharmaceuticals International, Inc. with the Securities and Exchange Commission on March 20, 2013). *

(a)(5)(B)		Form of Summary Advertisement. *

(a)(5)(C)		Press Release issued by Valeant Pharmaceuticals International, Inc. on April 3, 2013. *

(a)(5)(D)		Letter to Obagi shareholders from Valeant Pharmaceuticals International, Inc. *

(a)(5)(E)		Press Release issued by Valeant Pharmaceuticals International, Inc. on April 22, 2013. *

(a)(5)(F)		Press Release issued by Valeant Pharmaceuticals International, Inc. on April 23, 2013. *

(a)(5)(G)		Press Release issued by Valeant Pharmaceuticals International, Inc. on April 24, 2013. *

(a)(5)(H)		Press Release issued by Valeant Pharmaceuticals International, Inc. on April 25, 2013.

(b)		Not applicable.

(d)(1)		Agreement and Plan of Merger, dated as of March 19, 2013, by and among Valeant Pharmaceuticals International, Odysseus Acquisition Corp., Valeant Pharmaceuticals International, Inc. and Obagi Medical Products, Inc. (incorporated by reference to Exhibit 2.1 to Obagi Medical Products, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2013). *



(d)(2)		Amendment to Agreement and Plan of Merger, dated as of April 3, 2013, by and among Valeant Pharmaceuticals International, Odysseus Acquisition Corp., Obagi Medical Products, Inc. and Valeant Pharmaceuticals International, Inc. (incorporated by reference to Exhibit 2.1 to Obagi Medical Products, Inc.’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2013). *

(g)		Not applicable.

(h)		Not applicable.

*	Previously filed

EX-99.(A)(5)(H) 2 d528280dex99a5h.htm EX-99.(A)(5)(H) EX-99.(a)(5)(H)

Exhibit (a)(5)(H)

LOGO

International Headquarters

2150 St. Elzéar Blvd. West

Laval, Quebec H7L 4A8

Phone: 514.744.6792

Fax: 514.744.6272

Contact Information:

Laurie W. Little

949-461-6002

laurie.little@valeant.com

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES

TENDER OFFER FOR OBAGI MEDICAL PRODUCTS, INC.

Laval, Quebec — April 25, 2013 — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) today announced the expiration of the tender offer (the “Offer”) by a subsidiary of Valeant Pharmaceuticals International (“VPI”) to purchase all of the outstanding shares of Obagi Medical Products, Inc. (NASDAQ: OMPI) (“Obagi”) for a price of $24 per share in cash, without interest (less any applicable withholding taxes).

The Offer expired at midnight, New York City time, on April 25, 2013. American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised that, as of the expiration of the Offer, a total of 14,708,133 shares had been tendered into and not withdrawn from the Offer, representing approximately 84.12% of Obagi’s outstanding shares. Additionally, the depositary has advised that an additional 938,189 shares had been tendered by notice of guaranteed delivery. The condition to the Offer that at least a majority of the outstanding shares of Obagi common stock (on a fully diluted basis) be validly tendered and not properly withdrawn prior to the expiration of the Offer has been satisfied. Accordingly, all shares that were validly tendered and not properly withdrawn were accepted for payment and Valeant will promptly pay for all such tendered shares in accordance with the terms of the Offer. Valeant intends to exercise its top-up option to acquire additional Obagi shares. As a result of the tenders and the top-up option exercise, Valeant will own more than 90% of the outstanding Obagi shares (on a fully diluted basis) and expects to complete today the acquisition of Obagi through a “short form” merger under Delaware law.

As a result of the merger, Obagi will become a wholly owned subsidiary of VPI. In the merger, each remaining share of Obagi that was not validly tendered in the Offer will be cancelled and converted into the right to receive the same $24 per share in cash that was paid in the Offer. Following completion of the merger, the common stock of Obagi will no longer be listed for trading on the NASDAQ Global Select Market, which is expected to take effect as of the close of market today.

LOGO

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the acquisition by Valeant of Obagi. Statements including words such as “expects,” “intends,” “will,” or similar expressions are forward-looking statements. Because these statements reflect Valeant’s current views, expectations and beliefs concerning future events, these forward-looking statements are not guarantees of future events and involve risks and uncertainties. All forward-looking statements speak only as of the date they were made. The company assumes no obligation to publicly update any forward-looking statements, to reflect events, circumstances or changes in expectations after the date of this press release.

###

GRAPHIC 3 g528280img1.jpg GRAPHIC begin 644 g528280img1.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`1@+&`P$1``(1`0,1`?_$`,X``0``!@,!`0`````` M```````$!@<("0H"`P4!"P$!``$%`0$```````````````0"`P4&!P$($``` M!0,"`@<#!@H&!PD````!`@,$!0`&!Q$((1(Q$Y;6&%@)02(446&!,A47<9&A ML7*R(S,6"M%2TU65U?!"D]165QG!X8*28R0F-D@1``$#`@0#!`@!"`@#"0$` M``$``@,1!"$Q$@5!409A@2(3<9&AL=$R%`<5P>%"4F*2TB/P\7(S4U06%\*S M)+)#8W,T)34F-B?_V@`,`P$``A$#$0`_`-_BB)1$HB41*(E$2B)1$HB41*(E M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB M41*(E$2B)1$HB41*(E$2B)1%"+B'/\X%+^43!7@%7FF=%0/YLGD'Y:5_IZEY M:\I'-5`2=R#%HH)>8$W;I!LH)1Y@`W5K*$-RB)1`!TTU#3IJW$R>Z!>6N\H' M@$CAG?5C&N,`SIG_`$K1=7VW"?WU#_XFR_MZK^E'ZDGJ_,J_H_V)?5^9/MN$ M_OJ'_P`39?V]/I1^I)ZOS)]'^Q+ZOS+Y]MPG]]P_^),_[>JV0:#4,D]7YE[] M'^Q+ZOS+X$W"B8"%FH@QC"`%*619F,,R*+6__F,_3RN#=+M<)N.PZ6X$\Z[8HR2FG$1` MOI)LZOO#RJA)"];=!O'N$R24M;1DRR[#F*93]DX3+J*H!73/MMU#;[5O<=C= MPPNL[A]'.?FSPG%O`EQ`%#AQS72_MGU!;[7O46WWD,+[2Y?I<]^;,"13@22& MMH<.(Q7YT'\57.(D,6[[F,F=,#@8+@E]>(\-0%X`E`Y=!T$`,&N@\0KZM@L] MNEE_N8OIB*AP:VIKW+Z^AV3;)0'^7'Y)%0=+-9&.D&MQ3*;IE(LETW+)Z@H5Z`@LT<( MD.374`,7HJV_:;%[2SRHP"/U&_!4OV+;I&%ABCQ_8;\%^FWZ57J[X7W>;1+% MO#+61H*UL\64V;6)FF`D"O0=.+JB6:2;>]&K9DU=$"*OR.1)()&*(%*L99/@ M)!`?C7K3IB7I'=76KRY^WGY)'`5=V&F'LXKXLZXZ1EZ/W5]JYSWV!^21P`)[ M#IP]0&!624=X>V7_`)Q6Q]*$W_E=:FTU':M+!J.U?/&)MF_YQ6O_`+";_P`K MKU>IXP]LW_.*U_\`83?^5T13M8>?<09/EW,#C^^8NZYAHP4DG#&+;R@G19IJ M$1%==5RP;H(E%4_*`&/J8>CH&K8EC+_+!\8*MB6,O\L'QA49SQO^VA;8IIG` M[@<@@8.`@-8U]8YI; M9^%Q'7#M"@/B\N:2W?A+&:$?M"M1ZU(>:,[XKV\V/*9*S->,=8%@09#*SEX3 M+274@8)N4Q$Q>3;V,8/R1#'K5"EZYSU2.I@]^I.VV5YNL[K.T9JO1B&@@5'$ MXD=OJ5=E97FY7!LK%FN\S:VH%6YDYC(5/CFUX53R/<&>6^5@>SM:V._C,

MG[336A M53BB)B@(AH/'A^`1"H3'%S:G`X^]8V)[GL#G"CL?8:*%D'J,:R+3;.R=44/?59:;8MZMK9MY/#IMG9.J M*'T8J\_^@.&H#IJ'1J'`=*QJQB^".@A\@_CKVF&'S$T5+C32!\SG4]A^"LQS M#ZA&SO`%]1V,\S9UM7&]^3!E"P=K75&W='RUQ=4X^$4&V4`MU4+G(1R8I.:. M%T43F`/:`UD]OV#?=SBEFLX!(R,XD.``',U(IABLY8].;YND3Y=OA$C&'$ZF M@`=I)%._!>)`>I?L:N>]K-QQ"[A[5=7UD*XF5I65;*L)>\?)7+N`3,;03E`A"B8P@'&K\O36^01&6XA:UH%3_,C(I^_557/3._6<1EN M(6@`<)(S[GE7S)'ZP@'X<=>CH'0=-0Z>`_36$HX8/IJ6":)`/YK=+^6?NJN8 MCI[!'CT^P`Z1$P^P!`--?E$*=B]5+R9FQFIEU?`Q;U@/O?:6(AD]WC\71BW& MA8#F:<6ZA=`LQ)R#'*S38R`&Y^;4.82@701DBPW#Z$;F^.FWN?H#\?FPP]HQ M4INWW_T(W1\9&WNDT!XK\V&'M"JB'1[/H'4/H'VA4$LR'R(_QPK( M"WNK^!IU_(Q;"Z&<>NFG]I11I"*614.W,H**@`"H$U*)I1L+YFVMW22,_3.> MYM1B!II7OQY4Y&JN26.XQ['Y0]FO34)Y M?LBQN+;21*W^)NRY8RX0M9D M9VX!JT)(W''P[Z&C#NG'[,A7"Z1S'TT`>8-9ME8W>X@-LV:Y3D!2O;@2%D+7 M;KN^.BS;YDIR`I^4A5)QYD6TLJVG#WU8DH,[:5P-DWL+-?9TM%HR;)=%)PV> MM&\TQCGBK-TW6*=)4$^K5(/,41"K-S!/:2F*X`!&>-2"HUS;W%G*8IP`1GC4 MU]RION&W28$VIVW;]X;@,DPN,[:NBZ&=E0$E,M9I]]K73(,WL@SAV3.!C)5\ MHNHSCEE!-U75E*3WC%X:R+7;KV]);:M#G@5I6GOHI-KMM[>G3;-#GTK2H'O5 MM,IZL_IW0D>>6FMUF-H.)3%(JLG.M;RA8Q([@R:;E.I[IQ9:6[7N&8UL_B61M.D^I[YY9:6S7N;F-;`?:Y=KSU8O3QC MX]66>[H[$:1:#/X]61<15\I,2M.3K0<@[-:7PYFQTA`Q5`,(&+Q#4!"DG3.^ M0N#)(*/X@.8?<\^U4R=-;W%)Y4D/C&8#F'W./M5[&,LE6+F3']GY5QC. M/;^@F-S6==43\1]FS\#))]:QE&(ND&S@6KI+WB"=,@B''2L+-%+;W!MYQ1PS M]/N6&EBEM[@P3BCFY^E5%2_=E^G]8:H5"[*(E$2B)1$HB41*(E$2B)1$HB41 M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1 M$HB41*(E$2B)1$HB41*(E$2B*%7^N'Z(?G&B*"`UZUSF'6TT<,1W8JY$7-D#F5#P:CNQ M7YA'KO\`IP+[!=X$O)63#K-=N^X%S+Y!Q`JD@8D?;]?9'VIZOAZDZ M?^AN)6G=8<"ROB(`I6G(TYYU"P>5U`$.%6Y+J#,6BJ5ZJDKQ%?5L%W1.=L.> MH2:D7`_=O>AFEH9*CRF6!$(9VX*+*XDT2G(*;RUWZO7D,/UD15*(Z"(5H77? M2T/5FRN86?\`5VP):`*EQSP]2Y[]PNDX^J]D-TG3-VV.!VSMHX(55J\;J%$P'0=('*<@@(@)1`0'C7QMY,L=S M+;R-+9F2$%IS%*9KXE^FN([F:WD8YLK)""",10!<]3?*/XQJIS7,-'"A7C@6 M'2[!RY%-H/\`K'-PY$2E$ZJHB(%$$2AJ8ZNAM"D`-3"(>W2J5XM@39G@<,-8 MM;/)MH5.^KY*SG;E.8`ZV-:J(\T1;Z9SAUO5L&JO.L4=-7"AM0U*%6P1YE-. M/-6P1K^7'FJ&^KELA8;^MC67,*M6*)LC1$>;(^&I(Z:7Q##)]G-W#Z$:(+B4 MRJ"-RMQ6BU^00U3=ZC]6MMZ2WP[!OD-P]U;:4^5)R#7',UR`_GI MGJ"#;(;P=A-C-KX(+EUX#I*^X^P'9>I7;A"VEK<@R,(&!#B": M4S%36O:IWW'V)NS=1NNX0/H[P>>UPI2KL7`4X`G/M7G>J(G([KYX+21A^CJ M]5>2S,0<5&P,3'0,0Q:1<1"L&45$Q;%$J#*-C(]JBT8,&J)`*FF@T:HE3(4H M``%*%:6^2XDK=79J][BXGTGXE:+YES.775R[4^1Q=7TGXJTO?ON75VJ;5LI9 M6@VY9C(AV$?8.&[:()2.KGS3DB20LG%]OM$S`855'5V2R*JP:&T;(*'TT"LG MLVW?B>YLLW5$0HZ0_J1C-[N0&&/:LQT]MHW;>HMO?41`A\I_4BXO=R;D.]8# M]B=JW;Z1OJBEV89'O"5N3$OJ&X@M7+%K7A<;TSKXS=Q;$2`L;B?+_`%CR&)/I!X+I_44T M?672;^I+5@_$-M>8RQN/\NOS'`4!!U##`@XK:W(8.4-2B343`!3#Q#0PAI7) M0YA%6D4_+Q]M5QG36NC$9FG,BI]Z^GU$A@*`B;3AIQ$!U#0?QU;DD;I+6.`D M`5A[G&-QA/C'QR6LMLQ033_F4/5#$J9"";;?C8Q3`4H")Q8X:$YQ$`U$QN;C M\OMKKW4D;C]O-MD8<7T'>`%V7JETCOMKMICS+0,.8`IWK9JX``=`<``/Q>RN M2.>R/PR$!RXYJ:T`..-%\-T:CT!Q_P"RK@(TA]?#JS[BJB6^%U:4<#W4*UEO M61DX2!]53T-;AN"3BH&(BLVWZXD9N8>-(N.8,6\OCT!4>R;Q1%LT;HBH8W,H ML"`D?7,(`4\C)-]/>Y35VVV-C?V$WVY&D74$`E93YGS4+BT#*M6M]9"[C;1VNX M[=-]O&`?4P0"5M/F=-0N+:-%R*$,'`Q3`-`HF*8`X]`AJ`A\U>.!#0*T(<#W M8JV_6&AC<'ZVFO(8XK57]0?9AE'=UZM&3IW;EF.9PANOVU[(,#9:V^7BP?*, MX:0GC97RK%SUH7<1--3K(6Z&)4D.N2534.4O7NG]]L=DZ'M;?

G-YV[9NAK2+=H1-9SWTL4KJ`Z&EK- M9(I4T::D=M0K\O3.]6$^Y&Y9S:%O#M,=N?J#XEK%7QBR?,3$Y2",0J][8 MM.Z,5)Z1ZD3XA:.147$J9NN:G7;#SDU;J?I1VT_^][8[ZC99AX2PZ@T=O9R/ MKQ6I]6](3[0P;]LA%ST]?#IQT@X8]G(]F.J)ZZ[-.2])_>:GRD4(WQO&/@ M$0QA_55H( MJB)^NHY&E:>^BR9XD#JL68R2`@AR8ZL<@CH``'+;,9H`Z::::=&E:Q=D3WX?WKC3TFM?751MR6!9MU7#:5SW%:\5.SMBK2S MJSI29I/5+==SS'[+F7D:5<3)-GKV,#J!6`G6E2,8I3`!C`,W+`S:3CF,DT,6SM)P16Q8`AR+(.$E4CIG<>?4!U+6 MDW\UU'NDODDM;YSZ^(G)QIRRY\5HNX3W46[S^2XM89G@^(G)Y^.?%5.L:Q[5 MQI:,#8=BPK2WK1MAD6-@(-@3JV47'@NJN5HT2T`$FZ1UCR;`M5SQ1W`Z'2 MB[G2.>,>EY@9%SS"`BF73;^C>II>F=Z9>PFEL_P/IQ;4'V''T56U=%]1R], M]0,W"$TM7D!].51[CCZK\HNZ[4N6Q[GNS+QAGMNW;:6D=S!C%(T$<<"ON/;[Z_LX MKR'&.5@<8Y_T]REZIBG)7B]&:B4A(`GH`"!RB42F#4I@$!`0$/:4P#H-5V MP8"YLE.%,>U2`&`/;+DX$8K9Q])3=:;>,7&`KPD@7OK$;$AK6K`'Z=XJ2/UJ_"B^1O MNWT9)M$[]YL&_P#3O%33]:OPHLP`:]/#CTZ#S``>T0$.D`#7C7(8W&6T$DGS MKA\9=+")9/F5\FQ?`GWIY))>MP-`5LG'+IJ]5(J0.JE;M-U:\-%CSZ=8BP`0 M=K@&H:D3/35I5+/&''C_6]X>(CJ)O>$>/$-1'H]G11%P/S)_.OC6UIXGW8K50FG<1Z/OK>R=VS;YO9FROU.[6 MF).?EWJ@,+.L#.EL`M,R+IRN/5L(X@2RJBVIM-&L\H/U4N'8SJZ[Z#CMX_YG M4-@[3I&>BE!Z:M`[`05V0AW7?0D=M&/,Z@L':2/TM`%!Z:M`[`05E1]-&T)O MDCG#U%,CQ;QC?&\B?8?=3&2[7J9P=H^/3NH?!MMI)!UK`U[-3N+I?)Z%Y MUY1,3`)BZUH'4KV6DK.G[1VJU@%3R+R/$[\GKY+0^J)&VLS.G+)P^DLP'.I^ MF[](^\>O!97.8Q0`0#7WN.O2`=&H_+Q&M3E<^6.E/"'T[J?%:@^:1T?GFOEE M^7(4I[U@AW40ER[]_4MQAM7L7(]PX[QYL%M>-W39;OBTXJW;B+IH=N%T[RXP:X MQ8ZNW@,L\`NB;13IGI>7?+AH=N-XXQQM-<8L=7;3`4YXW[UF/3SW#7%M:\3 MEM;ILN9ESALDG&6X'$L9<-DXD@G#5V7L=)7NLP>X\L2VIYR[1@8P7Q&YUS( M**,0#JQ$0K)]#]4645Z-KN(61V=XTLDS&)!:VH.`&)%?:LYT-U1M\6Y-VNZA MCAVN\:62TK0N((;6HH!B1WK-%L.W9VKO]5[-==/;S M8RFI82!H9$0?F.UD]G#I`/YE/U.TNM()S;;L=B4`-J8W4Q^%`7`I0XF%$Y] M#`'$[)OX_\`YMMAY2_D"[3OV/VSVSLD'Y%LMNY)DP3(J]<-FJ:BS5LD=RY0 M;IJ.GSDK5DV=4Y-5W:YR$2)]910P%`C7(G6OU1UA<P./`>%'C3`YG)1I!1KV\OBM93UG8"W+N]4GT.;2NJ'B+FMZ=S3 M?S&;MV>C64U"S$[[ MC+');.<]S'-H035YR0R6#IZLD;4@U(].>)P5VR!Q.D`B/./O:#IIS!Q M%/7_`,.E8:V;(V-Y=_?`GVE82VFD,;FN=JE:3CWK$%ZOF0KDNK&.)-A&+9EU M#9B]0;)+7"1)2,Y325FX.CVX7%N`OXI=3%12B\?-EF22B@=4+A\4NNN@#N71 M[?,F^7S28+:-Q;R\VG@''D33T+=^BK9D;IM]W$$VMM$YS>7FT\`X\B:>A=6 M:/2UO',.U^[MI\OO3S#8DE<PMCR6--OK2WV+W6+-"R697D/C./G&3> M'?13,PMG"+D2$XSN5[;>L/H-^9OC MX&><7>+/(X.X9T)]BH-_+\;GKLOG;7>FR[-AW#3<=L%O:1P7>\5'6&4=V/& M2$DTL6;`'1A7<-F963F,ZWB42-$AUT.77?<+:8V7HWFS%-NO8P\4RUZ078\ MR:FGI64^XFR1Q[@-[LP/PR_8'@C+60'$5RJ34TY@]JV`":Z&UX#QU^?Y_IKF MT,CI+IF5B=R4@\0U89SN M=,#B`>\8"B_X_(`_/6^W7_X"WXG\4N/^3`N@78K]N+<#/\5N/^5"I_\`4T] M?%V_VVK?O2"GW6$=VN!3E<';D+3(JRN>W9B-5-(1<+\V)QA=2?;9:A['8Z01]AY<5@SW#>I+EA;8IO;]-7U-;=)BC>[;F"Y!''U^K%!ECG=5`QL MM$N(^X[-ETD$HU2[7K=D!S)(\I)$>82$37HW+T+:.E=M=U19]3=)/+]K\VL MKXQNTG4:8'23A2GA!XA=`VGI7;7=3V?4O2;]>U^;65G%CM)+B!@:$U%.`/$ M8K;QQ:0R6-\<)CJ;3'UF%$VFG%.W(XO$!XAS:UQ73+=RSC(X@>ESEQ4MFN MI9\@<0/2YRJ!7BH6O]_,W%_Z1N8NC7[R\)```/2/W@Q0&`_4I1,/S!72? MM3AU@W_R'_\`"ND_:H__`&YI_P#`?_PK,OML$#[=,`%$#$-A'%'(#J!@-8 M5OF8!]H"`UH.X?_`"-R#_CO]ZT+<:C.I1U+Q'@/R]/37@`#=`^6M4:-+-#?EJM#W^:+]-\<;Y%B?4% MQ7;O_P`+RO(1UG9^9QR.B%M9^&!O;&0%T4]"I,KY9-P8O%!#0)%NFP!^4/8-=W.J60B$TIG7+N7T-$V1H+G>(UI0 MX#V47+A_4+_YA_IJKRKC]9GM5S4[]1GK/Q7T1YN(E/T_P#?5)MYG9N9[5[( M]\OSL8>\_%5;P7F.Z\!Y5LO]F`G,VC+$>G:6%:+7.I=HBW[:Y-KGA MC>U[3IJ7"CN!J#7EZENZX.N:/W&6YC6Y,3:SK#S6-:[5$!4RH2QZJP(^T=`_$```?D``HB^#H(:\.`_+IIP$.G\`U M0X.J'-`)!JJ'!U0YH!<#56;\]@.#O4,QI9^+,Y-9`\'8^3+2R7#O8GX3[2^ M)MYT`2]N]5FE^1! M&>3JC#LIF5G=CZHW/INXDN]M;IFE;I?D0<:Y&H'+#@2%>Y%1,9!QL?#0S!M% M1$3'LHJ+C&216[./C8UNFT8,6J"8%31;LVJ)$TR@``4A0`.`5B'O?+Z>0UE M=6IYU))]IQ#Y9)9#-(:RDDD]I-3[5Y-V1L[+PSN.MNYEK.EW7UN-"'CIY M2.$BA#G,6+ETSQK@3I\P!UO`HZ#H/15RW>R%X=+$)K<9MJ17CF"#ZE<@>R-^ MN>$36]<6DD5/#(@^I62[/-B3#:'>N>[Y89MR;E^X=RU__>CEB8RA%V0>9D[T M)'H1;->-F+6@X)6,@HR/2%%M&%3,U;D'E2ZLO`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`Y3`D.G`>`Z?)6M-(BF< M^8^,TJWA[.8[5JT;'QRNF>QI>ZE0#GEV\>QV-M@"[O>G:^^2[=Q^4;PRA9M M@SF+K8M.6MO&R&-+;L&XG+5U/QMO6^Q@DY&F)ARU3.M)E>'=%U(/[/0@9Y M_4+G;0=EMK=L-LZ1KRZI+B6US))SKP"V3J29VR'8H+1MO:ND:\O!))+:T!) M<7=2:D0@Y M.N+DCA-XD"J8E,)A-N(ZKEFV2+8[ZUCFLX`?+U.<"TFN(+2#^D:`DC'L6YCK M">78XMAO[:.>P@'\L.Q91V97J+1%!T\!XZ(BFBJ]!)!` M7+A%,2K.1;I`2`J%YN0H"`".@<TD"Z,[W"("`G!M>'IK7%:27W)F<]T7\ MDG`5R''C7'!8ZFWI\/&F]67WW--R^54XR92JTZG5;(\-:9AW) MK<#X<,EL8ZJ:-G_`9+-IM-;GM.I]6RO#09ZL3X6X'PX4IFLD8)"(%L/6'* M4`.H&I.L-R%)C$(($!QU'ETT`>CHUK7](6L&"(OUT\?I(]Q5D.^OT]]MGJ M%8O^[3/UGB]>1ACO;#R'!BVC[^QU-"4-)2U9U5%44DW'(!'3-<%6CL@`"B?` MI@SVP=2;MTY]VU3.B#QXA0$.X9.#@#V@56R;!U+NO3DKW;7,Z(/'B%`0>YP M(![1BKR;=A4K?@8"26661@X:-AVRRW"RK>+8M8]%5<"`!.M730YQTX:C\E M823R3('1MQ`//N2P4_EN=6$4<...53A[5[>@_+\WMJFJCZ9N:Q^>H5L&M?U M&,.EP'E'V0K!Q0O<$/7=M =8IS((I% MZPY0U,(<V+I[J.;IJY=>P6S)+LM+0\EV#3R`(%<.V?I[JA_3%P;N.U;+>% MND/+G8`YX-(%30<%Z(W(:?:V_;$ M0WAHMO++6TSCV4L^^!:)\[@44C&$NHE`1'7#WMPZ\NGW;HQ'YCBX@)6) MO;OZ^Z?>>4(O,<7$`G,FIS)5;JBJHQ+]V7Z?UAHB[(E$2B)1$HB41(E$2 MB)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41 M(E$2B)1$HB41(E$2B)1$HB41(E$2B%7^N'Z(?G&B+IHB416-^HR7"CO9 MAN"@MP$0C<.-[OL>3LYQ;PK$1?SEPSJ8-[6:PCDY5/@IMG/=0Z;N"%$[4[?K M.($$!E;;>W6TWK-RLWD73'5;P%.7]`IFV7L^S[C'NUD]WU<;@17@X>CN7YU M7IOXY334^1KX$VA0'5A!%^J4"ZF.5#54YM-1$0"NOL^].\1Q-8VWC<0,23 M2IYX--5VL_???&!K(K:)[0W'4:$NYX--4'TY,<@/#(5\&`>CE:00G$>C0B75 M=:?Z`&O?][-Z_P`I#^^?X53_`+];_P#Y.W_>/\"FN(]N)G^3['G/\"JO"^BTP>Z#9'N. M#)]8_P`0C#/70Z![ID&S<4.;YA4`:N0_?+J".7_`-/"+;3D'5.KGBWE.N M1??O>VN+I+."E,..?;X,EM4^AIZ[%_+"QETX^(BF79 MAZ.2YAU9U,.J[P;CSO/REMURCBC&&+,9QN0IS(N-S1;A9/W"Y?HM&.#<"`[4>-#0$4KQ MK7(+.[3LL>X6;[^YDT6K"!@:.J>PT%5XUKD%'--^IK;S0XQ9F#$MU62T3L7 M:W.)R'9KW_`&OLC?6TP\L.<-+JAQ#>(&.-,<-?N-+-N#($E]L6Z"$)/6C:CUA&W',6S)-7SP72<9(2C=+J MW;19?K2G2(=/WZM2;%=1VL%WKB,=PX-:`34$TIJPIQX$J/+L-W%80;B7Q&& MX?I:`3J!-:A2E,>!DMCOQQ/)XGL7,[:Q\W!:&4[RLQL5MW..%FUP9(ELF MQ"DS9[VUH5:3N>%?MT5"'QI+B''2`$ MU\.=#RYJA^PW#+OR/J(0YK"YQ#CI:!0G4=.!H>62Z<4[^\)9D9S3NT(/K4T M7BN1S)&M+AL->'>W994'<[^R;B7M=%5^<'TA;UY1JD:[;JF0$J_8HG1'KI MW#8KZVH'3Q.D+M/@<2`ZFH!V`S&/',"KNNF] MPL[@V%TZ+S1'K+M1TAM#B26@\#P4=E;?;A#"]T6!8U^L\C,;PONT(B_E;;C[ M>RLW8]GS5PM+4:S5\Q[!PLXCB)7(\^$50:@\<$%%93JQ22.<=OV;<9[&6[ MB:UT$#M)-<7']G#'/C16=LV7<[W3JR./V7UJN#9 M[J2V-W(UODB%TM"2"6M&XCBAHZ?EK'3N4[Q)1[=+2,EFXF22;F0ZY3JNMZPIBABY=ON(8(K MDR5$QHUM?%2MD;8EI"2L?<%A[`]Z6GD1@>W'\')90O3'\,L^YHMS,,WP-[7OM%^WZI=0 MAE-$U>0Q3@&6EZ9W"VGB@FD:'2Q&1I!-"&Y@U`->ZG(K,2]7=E<16MP]NJ: M$R-+"2-S!!`(/=WJXJQ]S&/,@9MRK@#87>UO?#Z4>K=\[`!#0KQ.4;1[M MLK;J[UT21G(XZ$FGROTFOV>HH55,BYE$CD"'-87$%@R]+VEDCJ`8U!X5PI[: M]BPL^UW,5G'?%P,,CJ`5-<>>&`]O8I?OC/LC9FY;$>"SP+!U;^1,.YIRC7& M+E892(4Q)(X]8I1;%@DF+=\243O-4ZICG`Q#(%`H#S#I7#:,G@<[61.'-;R! MU$"O8,5>AVRSN;9\H%)6O:VE<#J(&?($^Q4HM_U'L"W)B[&5XR`R\$)BO"\ M'N%?0\G82L7%F1[Z01;R;-^YME^CU:ZS99,S<3'(5,Q3#?'3 M]W'<16AD@?)YP#JG`C&CO#4894JI7^GKF>S9)%64D`AQ(!&)#B6C'UKW< ME[^L(X?:8Q5R%!Y0A+BRE9DAD1E8S:R5):\K6L6'>P\=,7-=T-%OG7P3.,?3 M[1(R351VZ4,K^R2.!3"6];[#>7CIHHI8=,!H27$`G'!OAJ5PQ%FN5[$L^ M,O6VYBZ;3<3]S+.6Z2)IR.@UR)II)K)K@7#42+J-3D.!3&`J9@/5QVQ M78,?\UA,K@T4`9PWJWB\PN#C33Z@?713A<.\''=F2>3N&9D+I0;(%:+(ASAURB0D4`M#-IO'")K7-/G1N>D MBC6YU_)2JMMVZ=Y+6.:3/&YXJ3@UN=HO/B#,56JR:I51(8-.'%6_PZJ:OAT>7KU:CI+>8-.'%>=->H)@.`Q]AG+#U_E<=Y MNDVD/`7`A:9N6V9%U=K6PQ;WLP7?H244HVO%V5@L5NB[,DWAJ[EJ6S"9&@9'XOX&Z+%,Y=JO9 M`=@S$Y%5T6JADCIJ&NEFCD>^M6M=4L(H:.%!2H(R46]VN3 M;@U\LL;WO)!:UU2P@`T<,5#A3FJ_`(&`!#70?E#2H@*-2_=E^G]8:(NRB) M1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41( ME$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HBA5_KA^B'YQHB MZ:(E$5,M8-Q-G:'C+?R]9$5?D%#R?VS&Q,T9W\"VE00.V^!%HY;`JX305. M4HGYN7G'2B@W_3LV1>W;=CTWZ2$J;\6LG1%[D3L0V=P1A/$;>L=L%!UU51C MG)EAU_\`65=JAI\Q@HBFCPB[:=!#[G;3`!Z0!-\``MY_!5@^`MYJ29#'-ERE_VYE%_` M,G-^VE;UPVK;ES`<9(MZ[',.\N):G`X)`TEW4`S.L!BF$3-RZ"%5MO9(K M4V+#X2:D=HR/2;HR_$XRAF&1+R2N]&Y;D0=2Q599/(!(TM\ M$W#VQVA>2R+$=G)5/O+MUK%9EYT1 MFH'+&JG%+!F)4;3QI8Q+&A2VEAR5M6JAKS]<<=#`'"KCKR MX>X2AQUAVKO`I7U8+V3<+FHN6D^8QVKO`I7U8+P4=EFV1''DGBP,5Q)K(EKW M^\MS&&DI\SI#(/5I(_QE%30RWVY"7$26@NF3E!00,?C[Y^:_<;WN3KD73CJ MD#"VM!D>%**])U'N5S=BZ<29`TMK3@XFT-E'7,+"W3V$U//"H53=SW(VILV2ET9C+2W/`D$CT5"X(;6- MOS<;UZG&\."&1+_@\J7>P,]F#QL5`YM1H=SW0NC<2?!'H'8,J99S-N>[.=&ZI/ELT#L&5/0H\NVK!Z>1+ MIRLA8,8VOB^6$A'7G(LWTNRCKK2EH9W))S<-NM9!&W)>5>P!&AWB[0[H4" M@7K.`:6W7U\;9EL:Z(W5`Y8UP/O#FK#[[7!BO[)+CR3$DA(NS)N;41@62;82"4 M.J9HD/S%3`7I^H+^>=D]R\E\<9:WL!I7ER4N7J/=9+AD\I)?$PL!Y`TK[E/ MD)M]P_;V5[ASE$V4R;Y7NF&5MV:O19Y.Y-6!`.!`]RA/W2]FMFV>/DAP-.&'PX:)?&=@ M7#=\+D9MB,D;SMNVKILV!N)PF?X^+MB]U8A:[85L)#D2TGEH)H9?4HF$4" MZ"''6IKIHA3&E0>\9>Y5,?+"\05.EV/>,?912%%[8<`PL#)6M&8OM9K;TQBF MP=)PXME5V3[$<']K_9-@N$7"ZO6P#'[>>R74=32 M2#R)XJ^-QW`R1RQDTC<2#7(Y5_(I;E]G&VV=M_'5LRF-V[N-Q,U?,+!6_B[ M49VWXJ4PDHX:)&<,W+M9LKU9.8@\I=7;A:-E&/;G[<>"K'$XWL>"N2\+PB+=8Q]RW\SMR/O&80ZX'4ZPM M&-=Q%MM'O.J9,48>-?+))`4I?=4'74>-199Y7/$%?"SM4A^[[M/=R7CR3)(S02>(/`J;KAVWX+N MR.R!%7'C>W9AAE62M>,IBV8Z$9D9.VJB+E MN9LF@YCT'BH.W-L&` M[2@+;MFW\;P;&)M_P!OE:$=:0?/T\F-47+=&_)"8D7;N7F[I!L\.F9V]7< M'3Y2&$2E`7C?[BXDNJ:MIW=P,6JK&2;+G:R5W1K>2.50QP!X@10-!( M72NVW?V@]"J@WO=+.29[20Z9H![:"@X>;JVY8DNX+K4?VVN MP?WY=^.+XO.6@9F6@9BX[BQ2M#&LEW)2D8[;NU$HQK`MFQTBF(1PV**:@&`Q MM8\&Y7%QA)0,8'-QX:LP/25;CW"XDH)A_+:QW#`5QGZ\<=63D`]JJ7E;L?< M)['O2&R':7QZ9CA!7Q;Q7982Y6($,3EDHP)!;JS&YBAU@Z@-4/E='&Z.'`N% M/6H[[AT,!\C#S&8Y&5X1-@P;Y8^[,@7TREDR+"NVN[S-!A MD><2JLHE\7>#)L1)X`E$ABE]TI1$1&MU]/QK7DDM:UOX;I91!P;/U91!O", MTILJ5JLB2"YU>HBP9HB)A`2B7A2:\EN0&2FNC\O]2]GO[R[8UEU^AEWTK[@K MABE`A2D`1$"%0!,.HZ%!0U'VCH%6%&43LFO<;IP MJC/&&3\E#,/TU$\;0<5-0X,B-3%4F`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`VYN8,.H[6]TFNFG_P!&M/O[1%Q\3,OY6]TG8:T^ M_M$3Q,R_E;W2=AK3[^T1/$S+^5O=)V&M/O[1$\3,OY6]TG8:T^_M$3Q,R_E; MW2=AK3[^T1/$S+^5O=)V&M/O[1$\3,OY6]TG8:T^_M$3Q,R_E;W2=AK3[^T1 M/$S+^5O=)V&M/O[1$\3,OY6]TG8>T^_M$3Q,R_E;W2=A[3[^T3MXIXFI?RM[ MI.P]I]_:+VI3Q,R_E;W2=AK3[^T[>5*>)F7\K>Z3L/:??VB5>)F7\K>Z3L M-:??VE2O.S@GB9E_WND[#VGW]HF2>)J7\K>Z3L/:??VE$3Q,RX__EO=)V&M M/O[088C-!ADGB9E_WND[#6GW]KVI7M2GB9E_WND[#6GW]I4I4IXFI?RM[I M.P]I]_:\H#FO$\34OY6]TG8>T^_M>4")XF9?RM[I.PUI]_:]J4XUXIXF9?RM M[I.PUI]_:55(R3Q,R_E;W2=AK3[^T..:''`Y)XF9?RM[I.P]I]_:=O%$\3, MOY6]TG8:T^_M>U]J4\3,OY6]TG8:T^_MEE/$S+^5O=)V&M/O[2I2I3Q,R M_E;W2=AK3[^TJ4J4\3,OY6]TG8:T^_M>57F:>)J7\K>Z3L/:??VE`$3Q,R_E M;W2=AK3[^T1/$S+^5O=)V&M/O[1>U>)F7\K>Z3L/:??VB\3Q,R_E;W2=AK3 M[^T17'VA/71;4/<"UOW#:BLJS[/;MUM&S"XH@QCG+279M'D@V;NR\NHE( MLH700XT13'1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2 MB)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41 M(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1$HB41(E$2B)1 5$HB41(E$2B)1$HB41(E$2B+__9 ` end GRAPHIC 4 g528280img2.jpg GRAPHIC begin 644 g528280img2.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`+P+&`P$1``(1`0,1`?_$`+L``0``!@,!`0`````` M```````!`@4&!P@#!`D"P$!``$%`0$!``````````````(!`P0%!@<("1`` M``4"`@D"!`0"!0T```````$#!`4"!A$'$MD5665%B8((3%!$Q0546$B"8$R M\&B-45QD;'!T>%2DB,E1A@$0`"`0,"!`0#!0("P```````0(1`P0A!3%! M$@9182(3<10'@9&Q,A6AP='A4F"TC,6%PCQOX?B)4TZN1%3@UZ6FUR7$FHC/` MO?'#^GY""E7DR3TIYDPD"&)?Y!2J\4%5JI#2+XXD(NY%.G,K(D>(K&<9\!S MH#/`L1+B4;Z55@JB/_>M41FI<"!5$?MB%&15R+X5&D1?[/B:DNJ/-T9$C MQ^!_Q_U`2TXIID0````2Z18X8^I"#N1BZ,K1TKR)?F%[85?\HE!J>L2:?'3 MXD^D0-I2Z>95T6O(AI4_BZ^#(]JYTKDBG4O8%%;>3B7!HJK)&I+TULGR.@X;$14K-E4U"]R'K> M!]&-UW;:X[O@Y-AV;E'1/7RX-U\SZQ[>_P`HW=O=>U8F^;;NFUW<+(L]<6NN M254G1N,6JZJJJJ77;]69$A:U.GAZ#SA--I+5O@>">7,M.X<^LG+3N^U[8&R+68HH/;CN5^VB(9C6[72;-?K)!Y6FU;$NY5I3H M.NJDJZZZ:2]:B(YV,65QJS;]=RE:+5T\:+DO'[S'V_`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`NV,' M-S)]&'"5R?\`)BNIZ>2U_@+N%M^Y[M==K;;$KTZ-],4Y2Z5Q?2DW14JWR6O` MX[!SJRIS/E9^$R^O^U[ME[60C'5R1<))(O'T(VF3>TQ+B1;4&2S5&3JCER0J MKI(E?DUZ..C5A&_AY>+TO)BX]=>FJXTX_=55+F9M.?M<(7,ZUU"[7I;5$W& ME4GS:JM#(!BDO3)PEI.+HT]&GX-J73&4NFHG5$^F;2MF$7'MZG3QZL59IM6Z18K M+K5)TJ&2298>Q>A8F8K"'6O3J6K5N_>ET6G%UXNK\=/B4Q\QK+S/MN.O3+ MJZ8.\[.E4ZUHNY[=?(RD)H4U54?/C))L=;5ZA\R@R^8G550?P,QN<2>QQPZZR]"+B3-^E4@2-%52E:M)TTD=7 MH+\-IS;JJUZ)&F;/$ST3 M'T-]$N[;<9S[8W&2Y.W7S;ZE^#7E7P/O#_)U]3YXM^Y].M[NJ-J3=S&KHJRT MN1K_`++2\^!\F>4V9UVYYEV1FI8$FI%7AE]<4?O4JJP<$6 MB2L=,-JJVKI(\2K05JI^(^@-\VO&W3'O;-9^;2)5$NV>VO$N6J^3^6TT MF>FFH4YFNFH[>-E2_6E:ZU!XD9D)QQ+G;TZ4=&M6N7Y754YN MA9CME_Z?K>6<1%L%I23EB.LNJNB5:+7A4YOZ?=NQ[F[FQ]NN2C;Q6Y7 M+\Y:0A"RG.U\RINU=5MQ:2CEKJIX022\=&>F?4C$O=S=F;?]0G['ZC;O3P\J%IJ7MV MO5/"JHMJA:4;6M'7I1OO^XQ@?@-YHG41'2?C1G.6%5--9&704WCC35C352? MX&.9[8T[EP/'WH_BC@_I17_$;:/_`5K_A,E>)-"='BKXU4H^J-/C_DU2EAA MAH%E];NB7H5)>A%\"]AC[ZV^X<[JX_-7/]^1I^\'7>.ZRG^9YV17_N3-+/W MER5_](I.INU1?.D\_/%Q5HU76)NFLZHS^L`VZ1N?D.3:DLJ14&H2=9T4U&>! M^PW'T_N17<#ZIRMI6;R=Z3M6?T;/]<>-/E9U-Z\LGV8 MDG=5]YB916EE[4V;6ZUMVY;8O)"\UKQCJU)U=TSDEBM>V7<4I;CJHM!!2A: MD_KJZRQ,AS-V-M1MRM7YWDO?PH><[I^G+;['R>7=R:W;G5; MG&GM271TMLEZ]:T>G2DW4UC\_\`,-JPL?+[(E:)NVX:?)_4K%O.'L2WYJZ M;K+(R`9JW5G6]90EMIJS2[.3M-E1;RBZ5)DWKGJC,CT1NNV[3ADRW2VH.6. MNN/7^7WTMUKII+U)7W'CW+-E[/85ZT[DU",\J5(6:.6CE M"Y)3I7C`P]^U%FHLEEWFQXE3S>[6EP>'&9#FP+31OR"DK4NZ4\>+MI6NCQ^G M).`FT6\NA])9RYPM9JT8'7$XE4>EZ;3OK"C\W9WRW&TL?<+2EN>VU$4K=BM)6U+N[>NBW9B,R.SKG;8NJU)]@JD]AKFMJY8I MH\9.4SJ)-9$MFN@ZJ3Q.T3K?M)U2Y>/DRS],-ZW+8< M+N'>,&$;F1;V=)QDDUT2R\9233XIJJ?D_$L7(#R4S8R'SCA/!KS?E$IJ]YUI M)+^,OE!2T1BK8\G[8C**L+6NY,ZD8ZV/(:#9TT_<(M(S2F4R-VT(L:Z!=SML MQL^S+?=AATV8QK>LKC;>E91Y]/.OQ?!:7NX>TMJWOM__`!&[$45B6K3_`%#! M6M[&NT7KLQUD[,E2::JDW+6B:CL1^W1#UQ?@WXRPZ])4G'Y41#$Z"22H3E! MT_2HI-(DZ4R,DR+$B+1_`:_N^]./2ZS?YG\7QTU^\TGU:3G]3MYO MY/TY\VI5UE77U>R[\[<;-Z].6- M%JD:Z)ZK\-/L+E`L@``````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````$ITTG[D1_TP%$DFY+BRE%52YK@8;S^R7M_P`@ILE; M5_0]3\5YFB;DNF5B5 M+D)=2:X^=/X34?Q(\,LL?#N$S(A,M:Y=VVS"S(N2^:JYI>ERI;4-2;^1MW+ MBW#+&IC8UC?='5$:TIPH2J=+UD6DI49[GN#>LK>G"[DR:25?MI_&= M3W5WAN/>%VQ=SM/E[%NU'^A%1;^+Z=:U?F77FAD++YHYMY)Y@RM_+M;3R1N= M_>T5EK1;K%Y$7'>#^W)6UVEP3\JL]3>_5VS'33I6)).FEL[5-:HEJ:-"&' MGPP\2[:M6_\`GY$'&4J\(NG4OZ6E?@C&P.X;>T[1F;=A6E\YFVXV9W:M2C:Z MNJ=M+ATW&H]?/TCI4M7R-\5D<^+V\?LU+?OV9RGS5\<[\E+OLN](.%C)VN1 MA+F@W%N7GE_<3"4K22>VE>$:LF3MA1-6FM!M.NBNC$5VW[Y=M;?NFQ7["RMJW2Q&%V$FTNJ,U.%Q47YX32:I3@J MNADSR`R:5S\R%S0R,DKH(GG<9&O%ZV:;] M9FY4^0:AJT(UU$9E7A@=K`S?T_/AN"3;AL57@UPUI^XU?;>]Q[9WW%W^Q!7 M+V+>]U0K1.2X5=.1B7)[QXSHRHMK"Q'GDN_NO+_`"AB;?@$(2KVV;>GKO@ M;4M^JWH)N>Z8^5<8HT)IH+.:VK-O4YK0(CT::JB/)S-PQ<_+NY4+?3D7I.3 M?4WJ]6^"U;U,W?\`N78MRNYN[0VVY:SLF+ROE]D^GD\MF/-98,>M[#OI>?@(&'GI-=[EW=,;>,`Q3;SAUQZ+-2L6UR,C9=V)FY!W^GLQ\YCS"9U0"/+@<_0RLP\E))=!&A"BFM1-%!/YATTXJ&,/JM'+J:\ MDZ(U>X9^T95EXVT85W%?N]4G2[_R, MN&_G-QJI99N\J[-L=6WF#.(L>"D;D:W/-R43).U9!>)R9,?=7N=<)/C" M3XM:E1CYE.Y)QM;-RVBE&2ZKYTWK;PQPUVO-EOH+5+?+ MJTRII.FJ.U[E'`L9,()^WDV^B>MQ;4G73^5%/EP,#MWN!;+8S;%V+FL_'=F M:ZJ5@Y1G3@^$HQ:^!7<_?'CWR9RQELJLX+90N2W)6MN]:.$U5HZX+7N2,J- M6#O&S9]G6E6S=MOOL%V+]HJFN@I26%1TG52<-IWC+VSCD8LG"Y1U\'%O6+ M\4T6.V^X-X[-WJWO6PW)0O1C$Z:J5N3=823TE%J5&GKX--(JGC[E`PR"R7R MVR6B9V:N:-RUM&+M/N.XZD5)^;:Q29I)R4VJWH207EW=.%3A2FFDE5<:S(C MJ,BM;EN-_==UR,_)JYW)3KSDZU?+\"/<>\9/_WWTY>9>=V?^O+63^U MZF+/+7Q>5\I[T2:R:2< M-7)D53NA,B56HIDJZ/<9>S[K/9\J65!>F=JY"2X=4;D'!IO72C_`(S:]F=U M_P!T\B]EQM[=OXM_&DFZ)V\BV[4UP=6XLVK9IN4FJ";Q>APZ)).ERXH2^10 MNN5%!++)H?,6)"A132JC3KT2/#$\!IH3AGR M7)%1%20````````==TZ;,D:G#MP@U0HPTUG"M"5&/H6-:AE21F?MZ^H`I!W M3;I?X[#$>'J1R;4L/[9_``0ZJMW?L+S-KK`!U5;N_87F;76`#JJW=^PO,VNL M`'55N[]A>9M=8`.JK=W["\S:ZP`=56[OV%YFUU@`ZJMW?L+S-KK`!U5;N_87 MF;76`#JJW=^PO,VNL`'55N[]A>9M=8`.JK=W["\S:ZP`=56[OV%YFUU@`ZJM MW?L+S-KK`!U5;N_87F;76`#JJW=^PO,VNL`'55N[]A>9M=8`.JK=W["\S:ZP M`=56[OV%YFUU@`ZJMW?L+S-KK`!U5;N_87F;76`#JJW=^PO,VNL`'55N[]A> M9M=8`.JK=W["\S:ZP`=56[OV%YFUU@`ZJMW?L+S-KK`!U5;N_87F;76`#JJW M=^PO,VNL`'55N[]A>9M=8`.JK=W["\S:ZP`=56[OV%YFUU@`ZJMW?L+S-KK` M!U5;N_87F;76`#JJW=^PO,VNL`'55N[]A>9M=8`.JK=W["\S:ZP`=56[OV%Y MFUU@`ZJMW?L+S-KK`!U5;N_87F;76`#JJW=^PO,VNL`'55N[]A>9M=8`.JK= MW["\S:ZP`=56[OV%YFUU@`ZJMW?L+S-KK`!U5;N_87F;76`#JJW=^PO,VNL` M'55N[]A>9M=8`.JK=W["\S:ZP`=56[OV%YFUU@`ZJMW?L+S-KK`!U5;N_87F M;76`#JJW=^PO,VNL`'55N[]A>9M=8`.JK=W["\S:ZP`=56[OV%YFUU@`ZJMW M?L+S-KK`!U5;N_87F;76`#JJW=^PO,VNL`'55N[]A>9M=8`.JK=W["\S:ZP` M=56[OV%YFUU@`ZJMW?L+S-KK`!U5;N_87F;76`#JJW=^PO,VNL`'55N[]A>9 MM=8`.JK=W["\S:ZP`=56[OV%YFUU@!QEAC_,Y-KKBGMI/BZ>!)R;\B!7/;A&9_?X7UXBT+ M^LJ\1+I:K1LI1)U22_>1ZGMW##[_``Q>I'Z237X'CA_.7N$%**];ZOBBM=:D M#N:W,#PGX8C,L,2DFF)?QT_47.KQ6A",8Q:DDJ_B2GS#IZ$ET^#2?XD"N.W"_P#((C$_<_NC;2/X%Z_,QP(@X\:_?^XG M&/3+K]-::^EO^@B=RVZ?KU!#>V\FGO\#_G]3((TCRK\6V4<)<8RIC54EKP M_#]XIN2W<>X(EMMUE7BR;=77GXD.IK;],9^&,RP]3DFOP^/\XDTFNG@B#A%S]QK4'/WZ%]#Q_O)I_5^OT$NKR%)JM)/7R1$[GMW$C^_P`,6'P3:^O]L4KY%'! MNE&U3]HZGMS?T+S-KKA7[@[_*I(U2:.$ER3Q/TJJJ3J M,J</K]DQ_/Z#'V]/?\@!#MK@>P`!VUP/8``[:X'L``=M<#V``.VN M![``';7`]@`#MK@>P`!VUP/8``[:X'L``=M<#V``.VN![``';7`]@`#MK@>P M`!VUP/8``[:X'L``=M<#V``.VN![``';7`]@`#MK@>P`!VUP/8``[:X'L``= MM<#V``.VN![``';7`]@`#MK@>P`!VUP/8``[:X'L``=M<#V``.VN![``';7` M]@`#MK@>P`!VUP/8``[:X'L``=M<#V``.VN![``';7`]@`#MK@>P`!VUP/8` M`[:X'L``=M<#V``.VN![``';7`]@`#MK@>P`!VUP/8``[:X'L``=M<#V``.V MN![``';7`]@`#MK@>P`!VUP/8``[:X'L``=M<#V``.VN![``';7`]@`#MK@> MP`!VUP/8``[:X'L``=M<#V``.VN![``';7`]@`#MK@>P`!VUP/8``[:X'L`` M=M<#V``2%TWI>\#[GZ?]OQ_T8@"?MK@>P`!VUP/8``[:X'L``=M<#V``.VN! M[``';7`]@`#MK@>P`!VUP/8``[:X'L``=M<#V``.VN![``';7`]@`#MK@>P` M!VUP/8``[:X'L``[C/[5BI]O^WZ6!?-^C^FQT?71^9\CUP_#$`5`````'__9 ` end